+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
S

Actively Recruiting

Atrial fibrillation AF is a major cause of heart-related illness and death, especially among Asian patients who face higher risks of serious bleeding such as brain hemorrhage compared to non-Asians. This research, called the COhort of antithrOmbotic use and cLinical outcomes in patients with Atrial Fibrillation COOL-AF Phase 2, aims to study how antithrombotic medication use changes over time and how these changes affect health outcomes in people with AF. The study is observational and conducted across multiple centers in Thailand. Participants in this study have known or newly diagnosed non-valvular AF and are followed without any intervention or treatment assigned by the study. The study plans to enroll about 3680 patients over two years from 33 centers. Participants will be monitored every 6 months for up to 3 years to observe patterns of medication use, particularly warfarin and non-vitamin K antagonist oral anticoagulants NOACs, and clinical events including stroke, systemic embolism, bleeding, heart attacks, and heart failure. Throughout the study, patients will have regular check-ins every six months to track their medication usage and health status. Researchers will collect data on important outcomes such as rates of stroke, bleeding events, and quality of life. The studys primary focus is on long-term safety and effectiveness of antithrombotic treatments in this population. The total participation duration can be up to 3 years, ensuring thorough observation of clinical outcomes and treatment patterns.

Age: 18Years - 100YearsAll Genders
33 locations
E

Actively Recruiting

Researchers are evaluating whether starting norepinephrine early with rapid dose adjustments can improve outcomes in adults with septic shock. The trial focuses on reducing 28-day mortality, speeding up shock control, and minimizing fluid needs without raising treatment-related side effects. It compares early norepinephrine use to standard treatment with delayed norepinephrine as needed. Participants will receive either norepinephrine or a placebo infusion within one hour of septic shock diagnosis. The norepinephrine starts at 0.05 mcgkgmin and is adjusted every 15 minutes based on blood pressure, with a maximum dose of 0.15 mcgkgmin. Both groups have rescue norepinephrine available if necessary. Limb ischemia and vital signs are closely monitored for 24 hours during the infusion. Throughout the study, participants receive standard sepsis care including fluids, antibiotics, and organ support. Researchers will monitor clinical outcomes and safety for up to 28 days. Key measures include survival at 28 days, time to shock control, and durations of intensive care, hospital stay, mechanical ventilation, and vasopressor therapy. Safety assessments focus on adverse events like cardiac arrhythmias and pulmonary edema.

Age: 18Years +All GendersPhase Not Applicable
6 locations
F

Actively Recruiting

Researchers are evaluating the safety and effectiveness of osimertinib tablets combined with Datopotamab Deruxtecan intravenous infusion compared to osimertinib alone as a first treatment for participants with locally advanced or metastatic non-small cell lung cancer NSCLC that has specific EGFR mutations Ex19del andor L858R. This global Phase III, open-label, randomized study includes participants who have not received prior therapy for advanced disease, aiming to assess treatment benefits over approximately 8 years. Participants are randomly assigned to one of two groups one group receives osimertinib 80 mg orally once daily plus Datopotamab Deruxtecan 6 mgkg by intravenous infusion every 3 weeks, while the other group receives osimertinib 80 mg orally once daily alone. Treatment continues until disease progression, unacceptable side effects, or other discontinuation reasons. Visits occur every 3 weeks during treatment, with additional assessments every 6 weeks from cycle 7 to cycle 17, then every 12 weeks for those on osimertinib alone or after discontinuing Datopotamab Deruxtecan. Participants will attend regular visits for treatment administration and assessments, including scans and laboratory tests to monitor disease status and safety. Researchers will measure progression-free survival, overall survival, response rates, and the impact on brain metastases over the study period. Pharmacokinetics and immunogenicity of the drugs will also be evaluated. The study includes continuous safety monitoring and may last up to 8 years, with visits and evaluations scheduled throughout treatment and follow-up.

Age: 18Years +All GendersPhase 3
167 locations
G

Actively Recruiting

This trial evaluates the safety and effectiveness of Volrustomig in women with high-risk locally advanced cervical cancer FIGO 2018 stage IIIA to IVA who have not shown disease progression after platinum-based concurrent chemoradiation therapy CCRT. It is a global, randomized, double-blind, placebo-controlled Phase III study designed to assess outcomes in this specific patient population. Participants are randomly assigned in equal numbers to receive either Volrustomig or a placebo via intravenous infusion. The study compares these two groups to explore the potential benefits and risks of Volrustomig as a treatment following CCRT in women with high-risk locally advanced cervical cancer. Women taking part in the study will undergo multiple assessments over up to approximately seven years. Researchers monitor progression-free survival as the primary outcome, along with overall survival, response rates, duration of response, subsequent therapies, and safety. Additional evaluations include tumor progression, pharmacokinetics, immunogenicity, adverse events, and patient-reported symptoms and quality of life. Participants provide tumor samples and undergo regular health evaluations during this period.

Age: 15Years +FEMALEPhase 3
205 locations